Colchicine treatment can be discontinued in a selected group of pediatric Familial Mediterranean Fever (FMF) patients
Authors' conclusion
This study supports the concept of colchicine free remission in a minority of FMF patients (3%).
Study context
- Population
- Pediatric FMF patients in whom colchicine was discontinued, out of 646 followed in a referral FMF clinicof 646 FMF pediatric patients
- Participants
- 51 patients
- Exposure
- Successful vs failed cessation of colchicine therapy
- Group 1n = 21
- Group 2n = 30reference
- Outcome
- Predictive characteristics (genetic, demographic, clinical) for successful cessation of colchicine therapy
Methodological detailssingle-centre referral FMF clinic
- Single-centre referral FMF clinic
Main finding
As reported in the abstract
Characteristics prior to drug cessation
- Group 1 had no biallelic pathogenic MEFV mutations
- Group 1 did not require >1 mg/day of colchicine prior to cessation
Observational data: associations, not effects.
Further findings
"Severe attacks" (two or more FMF characteristic symptoms) · prior to drug cessation
P = 0.000067
Remission duration under colchicine treatment
P = 0.0036
Original publication
Colchicine treatment can be discontinued in a selected group of pediatric FMF patients. Pediatr Rheumatol Online J. Published 4 January 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →